The discovery of RFI-641 as a potent and selective inhibitor of the respiratory syncytial virus

https://doi.org/10.1016/S0960-894X(01)00150-0Get rights and content

Abstract

The design and synthesis of a new potent and selective inhibitor of the respiratory syncytial virus are described. This compound, RFI-641, emerged from analysis of the structure–activity relationship in a series of biphenyl triazine anionic compounds possessing specific anti-RSV activity. The key synthetic step involves coupling of diaminobiphenyl 11 with two equivalents of chlorotriazine 10 under microwave conditions. RFI-641 inhibited RSV in vitro and in vivo models.

The design and synthesis of RFI-641, a new potent and selective inhibitor of the respiratory syncytial virus, both in vitro and in vivo, are described.

  1. Download : Download full-size image

Section snippets

Acknowledgements

This paper is dedicated to the memory of Dr. Yakov Gluzman. The authors wish to thank Drs Stanley Lang, Tarek Mansour, Brian O'Hara, John O'Connell, Anna Gazumyan and George Ellestad for valuable discussions, Dr. Boris Feld for providing the assay data and Mr. Sanford Strunk for scale-up of RFI-641.

References (16)

  • S Jairath et al.

    Antiviral Res.

    (1997)
  • D.L Barnard et al.

    Antiviral Res.

    (1999)
  • D.M Shlaes

    Seminars in Respiratory and Critical Care Medicine

    (2000)
  • Hall, C. B.; McCarthy, C. A. In Principles and Practice of Infectious Diseases, 5th ed.; Mandell, G. L., Bennett, J....
  • Hall, C. B. Presented at the Symposium RSV after 43 years, Hutchinson Island in Stuart, FL, 8–11 November...
  • A Gazumyan et al.

    Curr. Pharm. Des

    (2000)
  • E De Clercq

    Int. J. Antimicrob. Agents

    (1996)
  • L.J Chen et al.

    J. Nat. Prod.

    (1998)
There are more references available in the full text version of this article.

Cited by (39)

  • Treatment of respiratory viral infections through inhalation therapeutics: Challenges and opportunities

    2022, Pulmonary Pharmacology and Therapeutics
    Citation Excerpt :

    Nasal administration of liposomal poly ICLC in mice before or shortly after influenza infection has shown inhibition of viral replication, providing a significant reduction in pulmonary viral titres and a higher survival rate of infected mice [121]. Intranasal administration of antiviral agents like CL-387626 [122], RF-641 [122–124], JNJ-2408068 [125–129] and AS-1411 [130] have shown good antiviral activity in various animal models for RSV infection. Poly ICLC [131,132], ALX0171 [133], ALN-RSV01 [134], and MDT-637 [135–137] were also studied in human subjects for their effectiveness against respiratory viral infections as shown in Table 2.

  • Drug candidates and model systems in respiratory syncytial virus antiviral drug discovery

    2017, Biochemical Pharmacology
    Citation Excerpt :

    The first trial is a Phase 1b study in which also the potential anti-viral effect of single dose of AK0529 will be studied in infants hospitalized with an RSV infection, the second trial is a phase 2 study. RFI-641 (Pfizer) is a small dendrimer-like compound with potent in vitro activity against both RSV-A and RSV-B laboratory strains and clinical isolates (EC50 values around 20 nM) [73]. The compound was shown to inhibit binding as well as fusion of RSV with cells and showed to be resistant to viruses showing a mutation at position 446 of the F-protein (Fig. 2A) [74,75].

  • Inhaled anti-infective chemotherapy for respiratory tract infections: Successes, challenges and the road ahead

    2015, Advanced Drug Delivery Reviews
    Citation Excerpt :

    RFI-641 (Fig. 2) from Wyeth-Ayerst is a potent analog of their original lead compound CL-387626 [230]. RFI-641 showed good efficacy following intranasal administration in mouse and African green monkey models of RSV infection at doses as low as 0.04 mg/kg [230–232]. VP-14637 (Fig. 2; syn.

  • Pyrimidine containing RSV fusion inhibitors

    2005, Bioorganic and Medicinal Chemistry Letters
View all citing articles on Scopus
View full text